中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2010, Vol. 45 Issue (15) :1197-1200    DOI:
��ҩ���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
��ʹ����ҩ�����Dz���̹
�ž��������£���С��
�й�ҽѧ��ѧԺ����Э��ҽѧԺ����Э��ҽԺ������ 100730

Download: PDF (403KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ 
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� �Dz���̹   ����������ø   ʹ��     
Abstract��
Keywords��   
�ո�����: 2012-01-01;
���ñ���:   
.��ʹ����ҩ�����Dz���̹[J]  �й�ҩѧ��־, 2010,V45(15): 1197-1200
.[J]  Chinese Pharmaceutical Journal, 2010,V45(15): 1197-1200
��
[1] OKAMOTO K, EGER B T, NISHINO T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor comp lex and mechanism of inhibition[ J ]. J Biol Chem�� 2003, 278 (3): 1848-1855.[2] Full Prescribing Information of Uloric [EB/OL]. http: // www. uloric. com/[3] MICHAEL A B H�� RALPH S J R, ROBERT L, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. A twenty-eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout[J]. Arthritis Rheum�� 2005, 52(3): 916-923.[4] BECKER M A, SCHUMACHER H R J R, WORTMANN R L, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout[J]. N Engl J Med�� 2005, 353(23): 2450-2460.[5] RALPH H�� SCHUMACHER J R, MICHAEL A, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial[J]. Arthritis Rheum�� 2008, 59(11): 1540-1548.
Copyright 2010 by �й�ҩѧ��־